Targets › ULBP5
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
[Isoform 1]: Binds and activates the KLRK1/NKG2D receptor, mediating natural killer cell cytotoxicity..; FUNCTION: [Isoform 3]: Down-regulates the expression of KLRK1 and stimulates natural killer cells to secrete IFNG..; FUNCTION: [Isoform 2]: Stimulates natural killer cells to secrete IFNG. (UniProt, Q6H3X3)
Open in Phaseline: the race on ULBP5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhejiang University | NKG2D CAR-NK cells NKG2D-targeted chimeric antigen receptor natural killer cells recognizing NKG2D ligands | ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 | Phase 1 | Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments | Dec 2026 |
Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments (2)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.